Literature DB >> 3275720

Characterization and growth factor requirements of SJL lymphomas. I. Development of a B cell growth factor-dependent in vitro cell line, cRCS-X.

J L Lasky1, N M Ponzio, G J Thorbecke.   

Abstract

Reticulum cell sarcomas (RCS) of SJL mice are completely dependent on host cells for their growth and therefore fail to grow in vitro. RCS cells induce marked proliferation in SJL Ly-1+2- T cells accompanied by lymphokine production. In an attempt to fully understand the host-tumor cell interaction, an RCS cell line, cRCS-X, was established in vitro from a transplantable tumor by the addition, every 3 wk, of gamma-irradiated syngeneic lymph node (LN) cells to the culture. cRCS-X maintains all of the characteristics of the parent tumor, RCS-X, including cell surface phenotype (Ks and I-As positive, Ds negative and B cell marker 14.8 positive), ability to stimulate host T cells, and ability to grow in nonirradiated but not in gamma-irradiated SJL mice. The growth factor requirements of cRCS-X were examined. It was found that human BCGF can replace gamma-irradiated LN cells in the maintenance of long term in vitro growth of cRCS-X. cRCS-X cells respond to human B cell growth factor (BCGF) or to recombinant murine interleukin (IL)-5 in a short term proliferation assay [( 3H]thymidine incorporation) in a dose-dependent manner in the presence and absence of fetal calf serum. BCGF also promotes colony formation in soft agar by cRCS-X cells. Although both IL-1 and interferon-gamma can synergize with BCGF in the induction of cRCS-X proliferation, these lymphokines, as well as IL-2, IL-3, granulocyte-macrophage colony-stimulating factor, and IL-4 have no effect on cRCS-X growth when added alone. In addition, it was shown that SJL LN cells produce both IL-4 and BCGF II activities as assayed on murine B cells, after stimulation with gamma-irradiated cRCS-X cells. In light of these results it is postulated that IL-5, [corrected] produced by syngeneic T cells [corrected] after stimulation with RCS, is essential for RCS growth, both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3275720

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Comparative time-dependent analysis of potential inflammation biomarkers in lymphoma-bearing SJL mice.

Authors:  Monica H Kristiansson; Vadiraja B Bhat; I Ramesh Babu; John S Wishnok; Steven R Tannenbaum
Journal:  J Proteome Res       Date:  2007-03-28       Impact factor: 4.466

Review 2.  Superantigens related to B cell hyperplasia.

Authors:  N M Ponzio; V K Tsiagbe; G J Thorbecke
Journal:  Springer Semin Immunopathol       Date:  1996

3.  Nitric oxide production in SJL mice bearing the RcsX lymphoma: a model for in vivo toxicological evaluation of NO.

Authors:  A Gal; S Tamir; S R Tannenbaum; G N Wogan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Mutagenesis associated with nitric oxide production in transgenic SJL mice.

Authors:  A Gal; G N Wogan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

5.  The Emu-bcl-2 transgene enhances antigen-induced germinal center formation in both BALB/c and SJL mice but causes age-dependent germinal center hyperplasia only in the lymphoma-prone SJL strain.

Authors:  E A Secord; J M Edington; G J Thorbecke
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

6.  Linkage of superantigen-like stimulation of syngeneic T cells in a mouse model of follicular center B cell lymphoma to transcription of endogenous mammary tumor virus.

Authors:  V K Tsiagbe; T Yoshimoto; J Asakawa; S Y Cho; D Meruelo; G J Thorbecke
Journal:  EMBO J       Date:  1993-06       Impact factor: 11.598

7.  Inhibition of tumor growth by elimination of granulocytes.

Authors:  L A Pekarek; B A Starr; A Y Toledano; H Schreiber
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

Review 8.  Endogenous mouse mammary tumor viruses (mtv): new roles for an old virus in cancer, infection, and immunity.

Authors:  Michael P Holt; Ethan M Shevach; George A Punkosdy
Journal:  Front Oncol       Date:  2013-11-26       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.